Managing the liabilities arising from Structural alerts: A safe philosophy for medicinal chemists

Current Medicinal Chemistry

Volumn 18, Issue 20, 2011, Pages 3116-3135

  Edwards, P J ^a   Sturino, C ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

Bioactivation; Covalent protein modification; Hepatotoxicity; Mechanism based CYP inactivation; Metabolic switching; Reactive intermediates; Structural Alerts

Indexed keywords

3 METHYLINDOLE DERIVATIVE; 5 (4 METHYLSULFONYLPHENYL) 6 PHENYLIMIDAZO[2,1 B]THIAZOLE; ALPIDEM; AMODIAQUINE; BENZODIAZEPINE DERIVATIVE; CARBUTAMIDE; CIMETIDINE; CINNAMIC ACID DERIVATIVE; CLOZAPINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 ISOENZYME; DIBENZODIAZEPINE; DICLOFENAC; FLUNITRAZEPAM; GLUTATHIONE; HYDROXYL GROUP; INDOLE DERIVATIVE; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOXAPINE; LUMIRACOXIB; MELOXICAM; METIAMIDE; MIANSERIN; MIBEFRADIL; PROSTAGLANDIN D2 RECEPTOR ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; QUETIAPINE; SUDOXICAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM;

AGRANULOCYTOSIS; ARTICLE; BONE MARROW TOXICITY; COVALENT BOND; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INACTIVATION; HUMAN; LIVER FAILURE; LIVER MICROSOME METABOLISM; LIVER TOXICITY; METABOLIC ACTIVATION; NITROSYLATION; NONHUMAN; PROTEIN MODIFICATION; REDUCTION; STEREOSPECIFICITY;

ANIMALS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS;

EID: 79960006368     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796391714     Document Type: Article

References (190)

1. Smith, D. A.; Johnson, D. E.; Park, B. K. Safety of drugs can never be absolute. Curr. Opin. Drug Discov. Devel., 2006, 9, 26-28. (Pubitemid 43099072)
2. Bresalier, R. S.; Sandier, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England J. Med., 2005, 352, 1092-110.
3. http://www.astrazeneca.com/search/?itemId=3891692 Accessed 19th August 2010.
4. http://www.tga.gov. au/media/2007/070811-lumiracoxib.htm Accessed 19th August 2010.
5. Kaitin, K. I.; Dimasi, J. A. Measuring the pace of new drug development in the user fee era. Drug Inf. J., 2000, 34, 673-680. (Pubitemid 30659501)
6. Gagnon, J. P.; Dickson, M. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discovery, 2004, 3, 417-429. (Pubitemid 38618124)
7. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery, 2004 3, 711-715. (Pubitemid 39173511)
8. Guengerich, F. P.; MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol., 2007, 20, 344-369. (Pubitemid 46548682)
9. Lasser, K. E.; Allen P. D.; Woolhandler, S. J.; Himmelstein D. L.; Wolfe, S. M.; Bor. D. H. Timing of new black box warnings and withdrawals for prescription medications. J. Amer. Med. Assoc., 2002, 287, 2215-2220. (Pubitemid 34441937)
10. Vervloet, D.; Durham S. ABC of allergies: Adverse reactions to drugs. Brit. Med. J., 1998, 316, 1511-1514. (Pubitemid 28224967)
11. Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.; Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee J. S.; Nakai, Y.; O'Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225. (Pubitemid 40753853)
12. Baillie, T. A. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem. Res. Toxicol., 2008, 21, 129-137. (Pubitemid 351219714)
13. Doss, G. A.; Baillie, T. A. Addressing metabolic activation as an integral component of drug design. Drug Metab. Rev., 2006, 38, 641-649. (Pubitemid 44903260)
14. Baillie, T. A. Approaches for the assessment of stable and chemically reactive drug metabolites in early clinical trials. Chem. Res. Toxicol., 2009, 22, 263-266.
15. Smith, D. A.; Schmid, E. F. Drug Withdrawals and the lessons within. Curr. Opin. Drug Discov. Devel., 2006, 9, 38-46. (Pubitemid 43099074)
16. Nassar, A.-E. F.; Lopez-Anaya, A. Strategies for dealing with reactive intermediates in drug discovery and development. Curr. Opin. Drug Discov. Devel., 2004, 7, 126-132.
17. Kalgutkar, A. S.; Soglia, J. R. Minimising the potential for metabolic activation in drug discovery. Expert Opin. Drug Metab. Toxicol., 2005, 1, 91-142.
18. Miller, E. C.; Miller, J. A. The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazabenzene. Cancer Res., 1947, 7, 468-480.
19. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie, T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 2004, 17, 3-16. (Pubitemid 38134055)
20. Obach, R. S.; Kalgutkar, A. S.; Soglia, J. R.; Zhao, S. X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol., 2008, 21, 1814-1822.
21. Bauman, J. N.; Kelly, J. M.; Tripathy, S.; Zhao, S. X.; Lam, W. W.; Kalgutkar, A. S.; Obach, R. S. Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol., 2009, 22, 332-340.
22. Gan, J.; Ruan, Q.; He, B.; Zhu, M.; Shyu, W. C.; Humphreys, W. G. In vitro screening of 50 highly prescribed drugs for thiol adduct formationcomparison of potential for drug-induced toxicity and extent of adduct formation. Chem. Res. Toxicol., 2009, 22, 690-698.
23. Liebler, D. C. Protein damage by reactive electrophiles: Targets and consequences. Chem. Res. Toxicol., 2008, 21, 117-128. (Pubitemid 351219713)
24. Yan, Z.; Easterwood, L. M.; Maher, N.; Torres, R.; Huebert, N.; Yost. G. S. Metabolism and bioactivation of 3-methylindole by human liver microsomes. Chem. Res. Toxicol., 2007, 20, 140-148. (Pubitemid 46220164)
25. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246. (Pubitemid 19001640)
26. Begley, T. J.; Rosenbach, A. S.; Ideker, T.; Samson, L. D. Damage recovery pathways in Saccharomyces cerevisiae revealed by genomic phenotyping and interactome mapping. Mol. Cancer Res., 2002, 1, 103-112. (Pubitemid 36306768)
27. Lindon, J. C.; Nicholson, J. K.; Holmes, E.; Antti, H.; Bollard, M. E.; Keun, H.; Beckonert, O.; Ebbels, T. M.; Reily, M. D.; Robertson, D.; Stevens, G. J.; Luke, P.; Breau, A. P.; Cantor, G. H.; Bible, R. H.; Niederhauser, U.; Senn, H.; Schlotterbeck, G.; Sidelmann, U. G.; Laursen, S. M.; Tymiak, A.; Car, B. D.; Lehman-McKeeman, L.; Colet, J. M.; Loukaci, A.; Thomas, C. Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. Toxicol. Appl. Pharmacol., 2003, 187, 137-146. (Pubitemid 36349345)
28. Dennehy, M. K.; Richards, K. A.; Wernke, G. R.; Shyr, Y.; Liebler, D. C. Cytosolic and nuclear protein targets of thiol reactive electrophiles. Chem. Res. Toxicol., 2006, 19, 20-29. (Pubitemid 43185458)
29. Guan, X.; Davis, M. R.; Tang, C.; Jochheim, C. M.; Jin, L.; Baillie, T. A. Identification of S-(N-butylcarbamoyl) glutathione, a reactive carbamoylating metabolite of tolbutamide in the rat, and the evaluation of its inhibitory effects on glutathionereductase in vitro. Chem. Res. Toxicol., 1999, 12, 1138-1143. (Pubitemid 30013522)
30. Sturino, C. F.; O'Neill, G.; Lachance, N.; Boyd, M.; Berthelette, C.; Labelle, M.; Li, L.; Roy, B.; Scheigetz, J.; Tsou, N.; Aubin, Y.; Bateman, K. P.; Chauret, N.; Day, S. H.; Lévesque, J. F.; Seto, C.; Silva, J. H.; Trimble, L. A.; Carriere, M. C.; Denis, D.; Greig, G.; Kargman, S.; Lamontagne, S.; Mathieu, M. C.; Sawyer, N.; Slipetz, D.; Abraham, W. M.; Jones, T.; McAuliffe, M.; Piechuta, H.; Nicoll-Griffith, D. A.; Wang, Z.; Zamboni, R.; Young, R. N.; Metters, K. M. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1, 2, 3, 4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem., 2007, 50, 794-806. (Pubitemid 46332991)
31. Lévesque, J. F.; Day, S. H.; Chauret, N.; Seto, C.; Trimble, L.; Bateman, K. P.; Silva, J. M.; Berthelette, C.; Lachance, N.; Boyd, M.; Li, L.; Sturino, C. F.; Wang, Z.; Zamboni, R.; Young, R. N.; Nicoll-Griffith, D. A. Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding. Bioorg. Med. Chem. Lett., 2007, 17, 3038-3043. (Pubitemid 46702635)
32. Cheng, K.; Wu, T.-J. K.; Wu, K. K.; Sturino, C.; Metters, M.; Gottesdiener, K.; Wright, S. D.; Wang, Z.; O'Neill, G.; Lai, E.; and Waters, M. G. Antagonism of the prostaglandin D2 receptor 1suppresses nicotinic acidinduced vasodilation in mice and humans Proc. Natl. Acad. Sci. U S A., 2006, 103, 6682-6687.
33. Banks, A. T.; Zimmerman, H. J.; Ishak, K. G.; Harter, J. G. Diclofenacassociated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse events. Hepatolog., 1995, 22, 820-827.
34. Ouellette, G. S.; Slitzky, B. E.; Gates, J. A.; Lagarde, S.; West, A. B. Reversible hepatitis associated with diclofenac. J. Clin. Gastroenterol., 1991, 13, 205-210.
35. Shen, S.; Marchick, M. R.; Davis, M. R.; Doss, G. A.; Pohl L. R. Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem. Res. Toxicol., 1999, 12, 214-22. (Pubitemid 29096071)
36. Tang, W.; Stearns, R. A.; Wang, R. W.; Chiu, S. H.; Baillie, T. A. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol., 1999, 12, 192-199. (Pubitemid 29096068)
37. Bannwarth, B.; Berenbaum, F. Lumiracoxib in the management of osteoarthritis and acute pain. Exp. Opin. Pharmacother., 2007, 8, 1551-1564. (Pubitemid 47082703)
38. Rordorf, C. M.; Choi, L.; Marshall, P.; Mangold, J. B. Clinical pharmacology of lumiracoxib a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet., 2005, 44, 1247-1266. (Pubitemid 41832566)
39. Kang, P.; Dalvie, D.; Smith, E.; Renner, M. Bioactivation of lumiracoxib by peroxidases and human liver microsomes: Identification of multiple quinone imine intermediates and GSH adducts. Chem. Res. Toxicol., 2009, 22, 106-117.
40. Li, Y.; Slatter, J. G.; Zhang, Z.; Li, Y.; Doss, G. A.; Braun, M. P.; Stearns, R. A.; Dean, D. C.; Baillie, T. A.; Tang, W. In vitro metabolic activation of lumiracoxib in rat and human liver preparations. Drug Metab. Dispos., 2008, 36, 469-473. (Pubitemid 351185763)
41. Mitchell, J. R.; Zimmerman, H. J.; Ishak, K. G.; Thorgeirsson, U. P.; Timbrell, J. A.; Snodgrass, W. R.; Nelson, S. D. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann. Inter. Med., 1976, 84, 181-192.
42. Mitchell, J. R.; Thorgeirsson, U. P.; Black, M.; Timbrell, J. A.; Snodgrass, W. R.; Potter, W. Z.; Jollow, H. R.; Keiser, H. R. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther., 1975, 18, 70-79.
43. Nelson, S. D.; Mitchell, J. R.; Timbrell, J. A.; Snodgrass, W. R.; Corcoran, G. B. 3rd, Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science, 1976, 193, 901-903.
44. Timbrell, J. A.; Mitchell, J. R.; Snodgrass, W. R.; Nelson, S. D. Isoniazid hepatotoxicity: the relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther., 1980, 213, 364-369. (Pubitemid 10109641)
45. Ridgewell, R. E.; Abdel-Monem, M. M. Stereochemical aspects of the glutathione S-transferase-catalyzed conjugation of alkyl halides. Drug Metab. Dispos., 1987, 15, 82-90. (Pubitemid 17014510)
46. Anders, M. W. Formation and fate of reactive intermediates of haloalkanes, haloalkenes and haloacids. Adv. Exp. Med. Biol., 2001, 500, 113-120. (Pubitemid 34106984)
47. Rafter, J. J.; Bakke, J. E. Biliary metabolites of the anti-inflammatory drug 2-acetamido-4-(chloromethyl) thiazole. Drug Metab. Dispos., 1982, 10, 654-656. (Pubitemid 13223700)
48. Zhang, J.; Ye, Z.; Lou, Y. Metabolism of melphalan by rat liver microsomal glutathione S-transferase. Chem-Biol. Interact., 2005, 152, 101-106. (Pubitemid 40517148)
49. Garner, C. E.; Sumner, S. C.; Davis, J. G.; Burgess, J. P.; Yueh, Y.; Demeter, J.; Zhan, Q.; Valentine, J.; Jeffcoat, A. R.; Burka, L. T.; Mathews, J. M. Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration. Toxicol. Appl. Pharmacol., 2006, 215, 23-36. (Pubitemid 44118396)
50. Ortiz de Montellano P. R.; Kunze K. L. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. J. Biol. Chem., 1980, 255, 5578-5585. (Pubitemid 10023584)
51. Ortiz de Montellano P. R.; Kunze K. L. Shift of the acetylenic hydrogen during chemical and enzymatic oxidation of the biphenylacetylene triple bond. Arc. Biochem. Biophys., 1981, 209, 710-712.
52. He, K.; Woolf, T. F.; Hollenberg, P. F. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J. Pharmacol. Exp. Ther., 1999, 288, 791-797. (Pubitemid 29119696)
53. Lin, H. L.; Kent, U. M.; Hollenberg, P. F. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther., 2002, 301, 160-167. (Pubitemid 34250292)
54. Foroozesh, M.; Primrose, G.; Guo, Z.; Bell, L. C.; Alworth, W. L.; Guengerich, F. P. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenaseenzymes. Chem. Res. Toxicol., 1997, 10, 91-102. (Pubitemid 27044913)
55. Boor, P. J.; Nelson, T. J. Biotransformation of the cardiovascular toxin, allylamine, by rat and human cardiovascular tissue. J. Mol. Cell. Cardiol., 1982, 14, 679-682. (Pubitemid 13224453)
56. Boor, P. J.; Sanduja, R.; Nelson, T. J.; Ansari, G. A. In vivo metabolism of the cardiovascular toxin, allylamine. Biochem. pharmacol., 1987, 36, 4347-4353. (Pubitemid 18016194)
57. Jurva, U.; Bissel, P.; Isin, E. M.; Igarashi, K.; Kuttab, S.; Castagnoli, N. Jr. Model electrochemical-mass spectrometric studies of the cytochrome P450-catalyzed oxidations of cyclic tertiary allylamines. J. Amer. Chem. Soc., 2005, 127, 12368-12377. (Pubitemid 41279264)
58. Rimoldi, J. M.; Puppali, S. G.; Isin, E.; Bissel, P.; Khalil, A.; Castagnoli, N. Jr., A novel and selective monoamine oxidase B substrate. Bioorg. Med. Chem., 2005, 13, 5808-5813. (Pubitemid 41247763)
59. Bissel, P.; Bigley, M. C.; Castagnoli, K.; Castagnoli, N. Jr. Synthesis and biological evaluation of MAO-A selective 1, 4-disubstituted-1, 2, 3, 6-tetrahydropyridinyl substrates. Bioorg. Med. Chem., 2002, 10, 3031-3041. (Pubitemid 34761883)
60. Bissel, P.; Castagnoli, N. Jr.; Penich, S. Studies on the cytochrome P450 catalyzed oxidation of 13C labeled 1-cyclopropyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine by 13C NMR. Bioorg. Med. Chem., 2005, 13, 2975-2980. (Pubitemid 40387505)
61. Gu, C.; Collins, R.; Holsworth, D. D.; Walker, G. S.; Voorman, R. L. Metabolic aromatization of N-alkyl-1, 2, 3, 4-tetrahydroquinoline substructures to quinolinium by human liver microsomes and horseradish peroxidase. Drug Metabol. Dispos., 2006, 34, 2044-2055. (Pubitemid 44837765)
62. Mateeva, N. N.; Winfield, L. L.; Redda, K. K. The chemistry and pharmacology of tetrahydropyridines. Curr. Med. Chem., 2005, 12, 551-571. (Pubitemid 40331051)
63. Sheweita, S. A. Drug-metabolizing enzymes: mechanisms and functions. Curr. Drug Metab., 2000, 1, 107-132.
64. Kalgutkar, A. S.; Obach, R. S.; Maurer, T. S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metal., 2007, 8, 407-447. (Pubitemid 47603408)
65. Kalgutkar, A. S.; Dalvie, D. K.; O'Donnell, J. P.; Taylor T. J.; Sahakian, D. C. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics. Curr. Drug Metab., 2002, 3, 379-424. (Pubitemid 34778004)
66. Maggs, J. L.; Tingle, M. D.; Kitteringham, N. R.; Park, B. K. Drug-protein conjugates-XIV: mechanism of formation of protein-arylating intermediates from amodiaquine, a myelotoxin and hepatotoxin in man. Biochem. Pharmacol., 1988, 37, 303-311. (Pubitemid 18039711)
67. Obach, R. S.; Kalgutkar, A. S.; Ryder, T. F.; Walker, G. S. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: Insights into the hepatotoxicity of sudoxicam. Chem. Res. Toxicol, 2008, 21, 1890-1899.
68. Duan, J.-D.; Jeffrey, A. M.; Williams, G. M. Assessment of the medicines lidocaine, prilocaine, and their metabolites, 2, 6-dimethylaniline and 2-methylaniline, for DNA adduct formation in rat tissues. Drug Metab. Dispos., 2008, 36, 1470-1475.
69. Monks, T. J.; Jones, D. C. The mechanism and toxicity of quinones, quinonimines, quinine methides, and quinine-thioethers. Curr. Drug Metab., 2002, 3, 425-438. (Pubitemid 34778005)
70. Chen, W.; Shockcor, J. P.; Tonge, R.; Hunter, A.; Gartner, C; Nelson, S. D. Protein and nonprotein cysteinyl thiol modification by N-acetyl-pbenzoquinone imine via a novel ipso adduct. Biochemistry, 1999, 38, 8159-8166.
71. Roychowdhury, S.; Vyas, P. M.; Reilly, T. P; Gaspari, A. A.; Svensson, C. K. Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J. Pharmacol. Exp. Ther., 2005, 314, 43-52. (Pubitemid 41058239)
72. Kedderis, G. L.; Miwa, G. T. The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab. Rev., 1988, 19, 33-62.
73. Gorlewska, K.; Mazerska, Z; Sowmski, P.; Konopa, J. Products of metabolic activation of the antitumor drug ledakrin (nitracrine) in vitro. Chem. Res. Toxicol., 2001, 14, 1-10. (Pubitemid 32064369)
74. Robertson, I. G., Bland, T. J.; Palmer, B. D. Effect of substituents on the metabolism of nitracrine in rat. Xenobiotica, 1996, 26, 559-569. (Pubitemid 26180432)
75. Kobayashi, H.; Kobayashi, S. Absorption, distribution, metabolism and excretion of 14C-labelled enantiomers of the calcium channel blocker benidipine after oral administration to rat. Xenobiotica, 1998, 28, 179-197. (Pubitemid 28102454)
76. Takakusa, H.; Masumoto, H.; Makino, C; Okazaki, O.; Sudo, K. Quantitaive assessment of reactive metabolite formation using 35S-labeled glutathione. Drug Metab. Pharmacokinet, 2009, 24, 100-107.
77. Rietjens, I. M. C. M.; den Besten, C.; Hanzlik, R. P.; van Bladeren, P. J. Cytochrome P450-catalysed oxidation of halobenzene derivatives. Chem. Res. Toxicol, 1997, 10, 629-635. (Pubitemid 27263780)
78. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukaryotic zincdependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci, USA, 2004, 101, 15064-15069. (Pubitemid 39391719)
79. Zhang, K. E.; Kari, PH.; Davis, M. R.; Doss, G.; Baillie, T. A.; Vyas, K. P. Metabolism of a dopamine D4-selective antagonist in rat, monkey and humans: Formation of a novel mercapturic acid adduct. Drug Metab. Dispos., 2000, 28, 633-642. (Pubitemid 30390401)
80. Murray, M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr. Drug Metab., 2000, 1, 67-84.
81. John, B. A.; Chasseaud, L. F.; Wood, S. G.; Forlot, P. Metabolism of the antipsoratic agent 5-methoxypsoralen in humans: comparison with rat and dog. Xenobiotica, 1992, 22, 1339-1351.
82. Joshi, E. M.; Heasley, B. H.; Chordia, M. D.; Macdonald, T. L. In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity. Chem. Res. Toxicol, 2004, 17, 137-143. (Pubitemid 38252492)
83. Kalgutkar, A. S.; Dalvie, D. K.; Castagnoli, N. Jr.; Taylor, T. J. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem. Res. Toxicol, 2001, 14, 1139-1162. (Pubitemid 32911452)
84. Mutlib, A. E.; Shockcor, J.; Chen, S. Y.; Espina, R. J.; Pinto, D. J.; Orwat, M. J.; Prakash, S. R.; Gan, L. S. Disposition of 1-[3-(aminomethyl) phenyl]-N-[3-fluoro-2'-(methylsulfonyl)-[1, 1'-biphenyl]-4-yl]-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC 423) by novel metabolic pathways. Characterization of unusual metabolites by liquid chromatography/mass spectrometry and NMR. Chem. Res. Toxicol, 2002, 15, 48-62. (Pubitemid 34106090)
85. Mutlib, A. E.; Chen, S. Y.; Espina, R. J.; Shockcor, J.; Prakash, S. R.; Gan, L. S. P450-mediated metabolism of 1-[3-(aminomethyl) phenyl]-N-[3-fluoro- 2'-(methylsulfonyl)-[1, 1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5- carboxamide (DPC 423) and its analogues to aldoximes. Characterization of glutathione conjugates of postulated intermediates derived from aldoximes. Chem. Res. Toxicol, 2002, 15, 63-75. (Pubitemid 34106091)
86. Potashman, M. H.; Duggan, M. E. Covalent modifiers: An orthogonal approach to drug design. J. Med. Chem., 2009, 52, 1235-1246.
87. Boelsterli, U. A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug interactions. Curr. Drug Metab., 2002, 3, 439-450. (Pubitemid 34778006)
88. Bryant, A. E. 3rd.; Dreifuss F. E. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology, 1996, 46, 465-469. (Pubitemid 26081333)
89. Tang, W.; Abbott, FS. Characterization of thiol-conjugated metabolites of 2-propylpent-4-enoic acid (4-ene VPA), a toxic metabolite of valproic acid, by electrospray tandem mass spectrometry. J. Mass Spectrom., 1996, 31, 926-936. (Pubitemid 26258973)
90. Grillo, M. P; Chiellini, G.; Touelli, M.; Bemet, L. M. Effect of α-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats. Drug Metab. Dispos., 2001, 29, 1210-1215. (Pubitemid 32800233)
91. Knights, K. M.; Drogemuller, C. J. Xenobiotic-CoA ligases kinetic and molecular characterization. Curr. Drug Metab., 2000, 1, 49-66.
92. Knights, K. M. Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acids. Clin. Exp. Pharmacol. Physiol., 1998, 25, 776-782. (Pubitemid 28442679)
93. 32P-Postlabeling with the DNA Adduct Formed in HL-60 Cells Treated with Hydroquinone. Chem. Res. Toxicol., 1996, 9, 593-598.
94. Macdonald, T. L.; Zirvi, K.; Burka, L. T.; Peyman, P.; Guengerich, F. P. Mechanism of cytochrome P-450 inhibition by cyclopropylamines. J. Am. Chem. Soc., 1982, 104, 2050-2052.
95. Cerny, M. A.; Hanzlik, R. P. Cytochrome P450-catalyzed oxidation of N-benzyl-N-cyclopropylamine generates both cyclopropanone hydrate and 3-hydroxypropionaldehyde via hydrogen abstraction, not single electron transfer. J. Am. Chem. Soc., 2006, 128, 3346-3354.
96. Silverman, R. B. Radical ideas about monoamine oxidase Acc. Chem. Res., 1995, 28, 335-342.
97. Guengerich, F. P.; Macdonald, T. L. Chemical mechanisms of catalysis by cytochromes P-450: A unified view. Acc. Chem. Res., 1984, 17, 9-16.
98. Vintém, A. P.; Price, N. T.; Silverman, R. B.; Ramsay, R. R. Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorg. Med. Chem., 2005, 13, 3487-3495. (Pubitemid 40545804)
99. Benedetti, M. S.; Plisnier, M.; Kaise, J.; Maier, L.; Baltes, E.; Arendt, C.; McCracken, N. Absorption, distribution, metabolism and excretion of[14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur. J. Clin. Pharmacol., 2001, 57, 571-582.
100. Masubuchi, N.; Makino, C.; Murayama, N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: Correlate of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol., 2007, 20, 455-464. (Pubitemid 46548692)
101. Williams, D. P.; Pirmohamed, M.; Naisbitt, D. J.; Maggs, J. L.; Park, BK. Neutrophil cytotoxicity of the chemically reactive metabolite (s) of clozapine: Possible role in agranulocytosis. J. Pharmacol. Exp. Ther., 1997, 283, 1375-1382. (Pubitemid 28016513)
102. Williams, D. P.; O'Donnell, C. J.; Maggs, J. L.; Leeder, J. S.; Uetrecht, J.; Pirmohamed, M.; Park B. K. Bioactivation of clozapine by murine cardiac tissue in vivo and in vitro. Chem. Res. Toxicol., 2003, 16, 1359-1364. (Pubitemid 37315224)
103. Mutlib, A.; Jiang, P.; Atherton, J.; Obert, L.; Seva Kostrubsky, S.; Madore, S.; Nelson, S. Identification of potential genomic biomarkers of hepatotoxicity caused by reactive metabolites of N-Methylformamide: Application of stable isotope labeled compounds in toxicogenomic studies. Chem. Res. Toxicol., 2006, 19, 1270-1283. (Pubitemid 44607313)
104. Le Fur, J. M.; Labaune, J. P. Metabolic pathway by cleavage of a furan ring. Xenobiotica, 1985, 15, 567-577. (Pubitemid 15046466)
105. Khojasteh-Bakht, S. C.; Chen, W. C.; Koenigs, L. L.; Peter R. M.; Nelson, S. D. Metabolism of (+) - pulegone and (+)-menthofuran by human liver cytochrome P450's: Evidence for formation of a furan epoxide. Drug. Metab. Dispos., 1999, 27, 574-580. (Pubitemid 29214468)
106. McMurtry, R. J.; Mitchell, J. R. Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephalosporine. Toxicol. Appl. Pharmacol., 1977, 42, 285-300. (Pubitemid 8238033)
107. Mitchell, J. R.; Potter, W. Z.; Hinson, J. A.; Jollow, D. J. Hepatic necrosis caused by furosemide. Nature, 1974, 251, 508-511.
108. Mitchell, J. R.; Nelson, W. L.; Potter, W. Z.; Sasame, H. A.; Jollow, D. J. Metabolic activation of furosemide to a chemically reactive hepatotoxic metabolite. J. Pharmacol. Exp. Ther., 1976, 199, 41-52.
109. Boyd, M. R. Role of metabolic activation in the pathogenesis of the chemically induced pulmonary disease: Mechanism of action of lung-toxic furan 4-ipomeanol. Environ. Health Perspect., 1976, 16, 127-138. (Pubitemid 8037538)
110. Zhang, K. E.; Naue, J. A.; Arison, B.; Vyas, K. P. Microsomal metabolism of the 5-lipoxygenase inhibitor L-739, 010: Evidence for furan bioactivation. Chem. Res. Toxicol., 1996, 9, 547-554. (Pubitemid 26082973)
111. Sahali-Sahly, Y.; Balani, S. K.; Lin, J. H.; Baillie, T. A. In vitro studies on the metabolic activation of the furanopyridine L-754, 394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Chem. Res. Toxicol., 1996, 9, 1007-1012. (Pubitemid 26301206)
112. Masubuchi, Y.; Horie T. Mechanism based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol., 1999, 12, 1028-1032. (Pubitemid 29498379)
113. Pea, F.; Milaneschi, R.; Baraldo, M.; Talmassons, G.; Furlanut, M. Isoniazid and its hydrazine metabolite in patients with tuberculosis. Clin. Drug Invest., 1999, 17, 145-154. (Pubitemid 29116587)
114. Nelson, S. D.; Gordon, W. P. Metabolic activation of hydrazines. Adv. Exp. Med. Biol., 1981, 136, 971-81.
115. Itano, H. A.; Hirota, K.; Hosokawa, K. Mechanism of induction of hemolytic anemia by phenylhydrazine. Nature, 1975, 256, 665-667.
116. Goldberg, B.; Stern, A. Generation of superoxide by the interaction of the hemolytic agent, phenylhydrazine, with human hemoglobin. J. Biol. Chem., 1975, 250, 2401-2403.
117. Misra, H. P.; Fridovich, I. The oxidation of phenylhydrazine: superoxide and mechanism. Biochemistry, 1976, 15, 681-687.
118. Sinha, B. K. Enzymatic activation of hydrazine derivatives. A spin-trapping study. J. Biol. Chem., 1983, 258, 796-801. (Pubitemid 13139328)
119. Jain, S. K.; Hochstein, P. Membrane alterations in phenylhydrazine- induced reticulocytes. Arch. Biochm. Biophys., 1980, 201, 683-687. (Pubitemid 11140695)
120. Gamberini, M.; Cidade, M. R.; Valotta, L. A.; Armelin, M. C. S.; Leite, L. C. C. Contribution of hydrazines-derived alkyl radicals to cytotoxicity and transformation induced in normal c-myc-overexpressing mouse fibroblasts. Carcinogenesis, 1998, 19, 147-155. (Pubitemid 28376837)
121. Mathison, B. H.; Murphy, S. E.; Shank, R. C. Hydralazine and other hydrazine derivatives and the formation of DNA adducts. Toxicol. Appl. Pharmacol., 1994, 127, 91-98. (Pubitemid 24248638)
122. Madsen, K. G.; Olsen, J.; Skonberg, C.; Hansen, S. H.; Jurva, U. Development and evaluation of an electrochemical method for studing reactive phase-I metabolites: Correlation to in vitro drug metabolism. Chem. Res. Toxicol., 2007, 20, 821-831. (Pubitemid 46953690)
123. Stout, M. D.; Herbert, R. A.; Kissling, G. E.; Suarez, F.; Roycroft, J. H.; Chhabra, R. S.; Bucher, J. R. Toxicity and carcinogenicity of methyl isobutyl ketone in F344N rats and B6C3F1 mice following 2-year inhalation exposure. Toxicology, 2008, 244, 209-219.
124. Sugiura, M.; Hayakawa, R.; Xie, Z.; Sugiura, K.; Hiramoto, K.; Shamoto, M. Experimental study on phototoxicity and the photosensitization potential of ketoprofen, suprofen, tiaprofenic acid and benzophenone and the photocrossreactivity in guinea pigs. Photodermatol. Photoimmunol. Photomed., 2002, 18, 82-89. (Pubitemid 34567591)
125. Boscá, F.; Miranda, M. A. Photosensitizing drugs containing the benzophenone chromophore. J. Photochem. Photobiol. B:Biol., 1998, 43, 1-26. (Pubitemid 28246032)
126. Formosa, P. J.; Bray, T. M.; Kubow, S. Metabolism of 3-methylindole by prostaglandin H synthase in ram seminal vesicles. Can. J. Physiol. Pharmacol., 1988, 66, 1524-1530. (Pubitemid 19046764)
127. Ruangyuttikarn, W.; Appleton, M. L.; Yost, G. S. Metabolism of 3-methylindole in human tissue. Drug Metab. Dispos., 1991, 19, 977-984.
128. Thornton-Manning, J.; Appleton, M. L.; Gonzalez, F. J.; Yost, G. S. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. J. Pharmacol. Exp. Ther., 1996, 276, 21-29. (Pubitemid 26150948)
129. Regal, R. A.; Laws, G. M.; Yuan, C.; Yost, G. S.; Skiles, G. L. Detection and characterization of DNA adducts of 3-methylindole. Chem. Res. Toxicol., 2001, 14, 1014-1024. (Pubitemid 32800157)
130. Skordos, K. W.; Skiles, G. L.; Laycock, J. D.; Lanza, D. L.; Yost, G. S. Evidence supporting the formation of 2, 3-epoxy-3-methylindoline: A reactive intermediate of the pneumotoxin 3-methylindole. Chem. Res. Toxicol., 1998, 11, 741-749. (Pubitemid 28350723)
131. Skiles, G. L.; Yost, G. S. Mechanistic studies on the cytochrome P450-catalyzed dehydrogenation of 3-methylindole. Chem. Res. Toxicol., 1996, 9, 291-297.
132. Nocerini, R.; Carlson, J. R.; Yost, G. S. Electrophilic metabolites of 3-methylindole as toxic intermediates in pulmonary oedema. Xenobiotica, 1984, 14, 561-564. (Pubitemid 14034076)
133. Ding, X. X.; Coon, M. J. Cytochrome P-450 dependent formation of ethylene from N-Nitrosoethylamines. Drug Metab. Dispos., 1988, 16, 265-269.
134. Davis, M. R.; Kassahun, K.; Jochheim, C. M.; Brandt, K. M.; Baillie, T. A. Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N, N'-Bis (2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro. Chem. Res. Toxicol., 1993, 6, 376-383. (Pubitemid 23146603)
135. Talcott, R. E.; Levin, V. A. Glutathione-dependent denitrosation of N, N'-Bis (2-Chloroethyl) N-nitrosourea (BCNU): Nitrite release catalyzed by mouse liver cytosol in vitro. Drug Metab. Dispos., 1983, 11, 175-176. (Pubitemid 13113903)
136. Le Gal, A.; Dréano, Y.; Lucas, D.; Berthou, F. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine. Toxicol. Lett., 2003, 144, 77-91. (Pubitemid 36952612)
137. Shank, R. C. Toxicology of N-nitroso compounds. Toxicol. Appl. Pharmacol., 1975, 31, 361-368.
138. Borel, A. G.; Abbott, F. S. Identification of Carbamoylated thiol conjugates as metabolites of the antineoplastic 1-(2-Chloroethyl)-3-cyclohexyl- 1-Nitrosourea (CCNU) in Rats and Humans. Drug Metab. Dispos., 1993, 21, 889-901. (Pubitemid 23298457)
139. Ju, C.; Uetrecht, J. P. Oxidation of a metabolite of indomethacin (desmethyldesclorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab. Dispos., 1998, 26, 676-680. (Pubitemid 28345851)
140. Dowers, T. S.; Qin, Z.-H.; Thatcher, G. R. J.; Bolton, J. L. Bioactivation of Selective Estrogen Receptor Modulators (SERMs). Chem. Res. Toxicol., 2006, 19, 1125-1137. (Pubitemid 44454028)
141. Maycock, A. L.; Abeles, R. H.; Salach, J. I.; Singer, T. P. The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavin of mitochondrial amine oxidase. Biochemistry, 1976, 15, 114-125.
142. Maycock, A. L. Flavin suicide inhibitor adducts. Methods Enzymol., 1980, 66, 294-302.
143. Sharma, U.; Roberts E. S.; Hollenberg, P. F. Inactivation of cytochrome P4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. Drug Metabol. Dispos., 1996, 24, 669-675.
144. Chen, Q.; Doss, G. A.; Tung, E. C.; Liu, W.; Tang, Y. S.; Braun, M. P.; Didolkar, V.; Regina, W.; Stearns, R. A.; Evans, D. C.; Baillie, T. A.; Tang, W. Evidence for the bioactivation of zompepirac and tolmetin by the oxidative
145. Ehlhardt, W. J.; Woodland, J. M.; Worzalla, J. F.; Bewley, J. R.; Grindey, G. B.; Todd, G. C.; Toth, J. E.; Howbert, J. J. Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas. Chem. Res. Toxicol., 1992, 5, 667-673.
146. Henderson, R. F. Species differences in the metabolism of olefins. Implications for risk assessment. Chem-Biol. Interact., 2001, 135-136, 53-64. (Pubitemid 32530479)
147. Hurst, H. E. Toxicology of 1, 3-butadiene, chloropene, and isoprene. Rev. Environ. Contam. Toxicol., 2007, 189, 131-179.
148. Mizutani, T.; Suzuki, K. Relative hepatotoxicity of 2-(substituted phenyl) thiazoles and substituted thiobenzamides in mice: evidence for the involvement of thiobenzamides as ring cleavage metabolites in the hepatotoxicity of 2-phenylthiazoles. Toxicol. Lett., 1996, 85, 101-105.
149. Mizutani, T.; Yoshida, K.; Kawazoe, S. Formation of toxic metabolites from thiabendazole and other thiazoles in mice: Identification of thioamides as ring cleavage products. Drug Metab. Dispos., 1994, 22, 750-755. (Pubitemid 24307490)
150. Kassahun, K.; Pearson, P. G.; Tang, W.; McIntosh, I.; Leung, K.; Elmore, C.; Dean, D.; Wang, R.; Doss, G.; Baillie, T. A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation and thiazolidinedione ring scission. Chem. Res. Toxicol., 2001, 14, 62-70. (Pubitemid 32064376)
151. Patel, N. N.; Crincoli, C. M.; Kennedy, E. L.; Frederick, D. M.; Tchao, R.; Harvison, P. J. Effect of gender, dose, and time on 3-(3, 5-dichlorophenyl) - 2, 4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. Xenobiotica, 2008, 38, 435-449. (Pubitemid 351380287)
152. Nadanaciva, S.; Dykens, J. A.; Bernal, A.; Capaldi, R. A., Will, Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol. Appl. Pharmacol., 2007, 223, 277-287. (Pubitemid 47362220)
153. Hall, J. H.; McDonnell, D. P. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol. Endocrinol., 2007, 21, 1756-1768. (Pubitemid 47173789)
154. Haskins, J. R.; Rowse, P.; Rahbari, R.; de la Iglesia, F. A. Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch. Toxicol., 2001, 75, 425-438. (Pubitemid 32905560)
155. Fajardo, T. T.; Guinto, R. S.; Cellona, R. V.; Abalos, R. M.; Dela Cruz, E. C.; Gelber, R. H. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am. J. Trop. Med. Hyg., 2006, 74, 457-461. (Pubitemid 46774370)
156. DeBarber, A. E.; Mdluli, K.; Bosman, M.; Bekker, L. G.; Barry, C. E. III. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Nat. Acad. Sci. USA, 2000, 97, 9677-9682. (Pubitemid 30650835)
157. Ruse, M. J.; Waring, R. H. The effect of methimazole on thioamide bioactivation and toxicity. Toxicol. Lett., 1991, 58, 37-41.
158. Chieli, E.; Malvaldi, G. Role of the P-450 dependent and FAD-containing monooxygenases in the bioactivation of thioacetamide, thiobenzamide and their sulfoxides. Biochem. Pharmacol., 1985, 34, 395-396. (Pubitemid 15163142)
159. Yeung, J. H.; Breckenridge, A. M.; Park, B. K. Drug protein conjugates-VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates. Biochem. Pharmacol., 1983, 32, 3619-3625. (Pubitemid 14205374)
160. O'Donnell, J. P.; Dalvie, D. K.; Kalgutkar A. S.; Scott Obach, R. S. Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab. Dispos., 2003, 31, 1369-1377. (Pubitemid 37310326)
161. Onderwater, R. C.; Commandeur, J. N.; Groot, E. J.; Sitters, A.; Menge, W. M.; Vermeulen, N. P. Cytotoxicity of a series of mono-and di-substituted thiourea in freshly isolated rat hepatocytes: a preliminary structure-toxicity relationship study. Toxicology, 1998, 125, 117-129. (Pubitemid 28162640)
162. Scott, A. M.; Powell, G. M.; Upshall, D. G.; Curtis, C. G. Pulmonary toxicity of thioureas in the rat. Environ. Health Perspect., 1990, 85, 43-50. (Pubitemid 20315280)
163. Steele, V. E.; Morrissey, R. E.; Elmore, E. L.; Gurganus-Rocha, D.; Wilkinson, B. P.; Curren, R. D.; Schmetter, B. S.; Louie, A. T.; Lamb, J. C. 4th; Yang, L. L. Evaluation of two in vitro assays to screen for potential developmental toxicants. Fundam. Appl. Toxicol., 1988, 11, 673-684.
164. Wittmann, J.; Steib, A.; Liebich, H. G.; Hammel, W. Lung development under the influence of thiourea and L-thyroxine. Retarding and toxic effects of thiourea. Res. Commun. Chem. Pathol. Pharmacol., 1987, 58, 199-214. (Pubitemid 17163265)
165. Dieke, S. H.; Richter, C. P. Acute toxicity of thiourea to rats in relation to age, diet, strain, and species variation. J. Pharmacol. Exp. Ther., 1945, 83, 195-202.
166. Fitzhugh, O. G.; Nelson, A. A. Liver tumors in rats fed thiourea or thioacetamide. Science, 1948, 108, 626-628.
167. Uckun, F. M.; Tibbles, H. E.; Venkatachalam, T. K.; Erbeck, D. In vivo pharmacokinetics, metabolism, toxicity, and anti-HIV activity of N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)] thiourea (HI-443), a potent nonnucleoside inhibitor of HIV reverse transcriptase. Arzneimittel Forschung, 2007, 57, 483-496. (Pubitemid 47234864)
168. Smith, P. B.; Crespi, C. Thiourea toxicity in mouse C3H/10T1/2 cells expressing human flavin-dependent monooxygenase 3. Bioch. Pharmacol, 2002, 63, 1941-1948.
169. Mizutani, T.; Yoshida, K.; Murakami, M.; Shirai, M.; Kawazoe, S. Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: Structuretoxicity and metabolic studies. Chem. Res. Toxicol, 2000, 13, 170-176. (Pubitemid 30169961)
170. Hollinger, M. A. Covalent binding of[14C] thiourea to protein in lungs from endotoxin-treated rats. Toxicol Appl Pharmacol, 1983, 70, 163-164. (Pubitemid 13005099)
171. Hollinger, M. A.; Giri, S. N.; Budd, E. A pharmacodynamic study of[14C]thiourea toxicity in mature, immature, tolerant, and nontolerant rats. Toxicol Appl Pharmacol, 1976, 37, 545-556.
172. Stevens, G. J.; Hitchcock, K.; Wang, Y. K.; Coppola, G. M.; Versace, R. W.; Chin, J. A.; Shapiro, M.; Suwanrumpha, S.; Mangold, B. L. In vitro metabolism of N-(5-Chloro-2-methylphenyl)-N'-(2-methylpropyl) thiourea: Species comparison and identification of a novel thiocarbamide-glutathione adduct. Chem. Res. Toxicol, 1997, 10, 733-741. (Pubitemid 27315105)
173. Castagnoli, N. Jr., Chiba, K., Trevor, A. J. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Life Sci, 1985, 36, 225-230. (Pubitemid 15193982)
174. Shi, H.; Noguchi, N.; Xu, Y.; Niki, E. 1-Methyl-4-phenyl-2, 3-dihydropyridinium is transformed by ubiquinone to the selective nigrostriatal toxin 1-methyl-4-phenylpyridinium. FEBS Letters, 1999, 461, 196-200. (Pubitemid 29533332)
175. Trevor, A. J.; Castagnoli, N.; Singer T. P. The formation of reactive intermediates in the MAO-catalyzed oxidation of the nigrostriatal toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Toxicology, 1988, 49, 513-519.
176. Singer, T. P.; Ramsay, R. R. Mechanism of the neurotoxicity of MPTP: An update. FEBS Letters, 1990, 274, 1-8.
177. Byron, J. W. Bone-marrow toxicity of metiamide. Lancet, 1976, 308, 1350.
178. Byron, J. W. Cimetidine and bone-marrow toxicity. Lancet, 1977, 310, 555-556. (Pubitemid 8186318)
179. Mizuno, K.; Katoh, M.; Okumura, H.; Nakagawa, N.; Negishi, T.; Hashizume, T.; Nakajima, M.; Yokoi, T. Metabolic activation of benzodiazepines by CYP3A4. Drug Metab. Dispos., 2009, 37, 345-351.
180. Hare, R. L.; Holcomb, B.; Page, O. C.; Stephens, J. W. Toxicity of carbutamide; report of a fatal case of bone-marrow depression and anuria. N. Engl J. Med., 1957, 226, 74-76.
181. Wu, Y. J.; Davis, CD.; Dworetzky, S.; Fitzpatrick, W. C.; Harden, D.; He, H.; Knox, R. J.; Newton, A. E.; Philip, T.; Polson, C.; Sivarao, D. V.; Sun, L. Q.; Tertyshnikova, S.; Weaver, D.; Yeola, S.; Zoeckler, M.; Sinz, M. W. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl) ethyl]-3-(4-fluorophenyl) acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition J. Med. Chem., 2003, 46, 3778-3781. (Pubitemid 37034130)
182. M. D.; Jewell, H.; Maggs, J. L.; O'Neill, P. M.; Park, B. K. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol, 1995, 50, 1113-1119.
183. Trimble, L. A.; Chauret, N.; Silva, J. M.; Nicoll-Griffith, D. A.; Li, C.-S.; Yergey, J. A. Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766, 112. Bioorg Med. Chem. Lett, 1997, 7, 53-56. (Pubitemid 27008529)
184. Roy, P.; Leblanc, Y.; Ball, R. G.; Brideau, C.; Chan, C. C.; Chauret, N.; Cromlish, W.; Ethier, D.; Gauthier, J. Y.; Gordon, R.; Greig, G.; Guay, J.; Kargman, J.; Lau, C. K.; O'Neill, G.; Silva, J.; Thérien, M.; van Staden, C; Wong, E.; Xu, L., Prasit, P. A new series of selective COX-2 inhibitors: 5, 6-diarylthiazolo[3, 2-b][1, 2, 4]triazoles. Bioorg. Med. Chem. Lett., 1997, 7, 57-62. (Pubitemid 27008530)
185. Roberts, P.; Kitteringham, N. R.; Park, B. K. Elucidation of the structural requirements for the bioactivation of mianserin in-vitro. J. Pharm. Pharmacol, 1993, 45, 663-665. (Pubitemid 23226762)
186. Samuel, K.; Yin, W.; Stearns, R. A.; Tang, Y. S.; Chaudhary, A. G.; Jewell, J. P; Lanza, T. Jr.; Lin, L. S.; Hagmann, W. K.; Evans, D. C.; Kumar, S. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectroscopy and tritium labeling techniques. J. Mass Spectrom., 2003, 38, 211-221. (Pubitemid 36305716)
187. Durand, A.; Thénot, J. P.; Bianchetti, G.; Morselli, P. L. Comparative pharmacokinetic profile of two imidazopyridine drugs: Zolpidem and Alpidem. Drug Metab. Rev., 1992, 24, 239-266.
188. Riley, R. J.; Grime, K.; Weaver, R. Time-dependent CYP inhibition. Expert. Opin. Drug Metab. Toxicol, 2007, 3, 51-66. (Pubitemid 47315418)
189. Polasek, T.; Miners, J. O. In vitro approaches to investigate mechanismbased inactivation of CYP enzymes. Expert. Opin. Drug Metab. Toxicol, 2007, 3, 321-329. (Pubitemid 47316027)
190. Fontana, E.; Dansette, P. M.; Poli, S. M. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr. Drug Metab., 2005, 6, 413-454. (Pubitemid 41300789)